FlandersBio on Twitter

Follow us on Twitter

Archive for July 2014 - News

Archive for July 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ThromboGenics’ JETREA Nominated for 2014 Prix Galien USA

31.07.2014

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA® (ocriplasmin) has been nominated for the 2014 Prix Galien USA Award in the Best Biotechnology Product category. This is the second time that JETREA®, a novel pharmacological treatment for symptomatic vitreomacular adhesion (VMA), has been nominated for this award. This latest nomination follows last month’s nomination of JETREA® for the Prix Galien UK Award. read more

genae Opens Offices in London

31.07.2014

genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced today the incorporation of genae UK in London. read more

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

23.07.2014

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases. read more

ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology®

22.07.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its successful confirmatory clinical validation study of ConfirmMDx® for Prostate Cancer has been highlighted by Elsevier, publisher of The Journal of Urology®, in a press release entitled "New, Accurate Epigenetic Test Could Eliminate Unnecessary Repeat Biopsies for Prostate Cancer." [http://www.eurekalert.org/pub_releases/2014-07/ehs-nae072114.php] read more

Porphyrio Raises €850.000 in Series A Funding

18.07.2014

Porphyrio, a pioneer in smart management solutions for high-end livestock producers, today announced it has raised €850.000 in a Series A round of funding from University of Leuven, Gemma Frisius Fund (seed capital fund of the University of Leuven) and the SOFI II-fund of the Flemish Government (dedicated to spin-offs of the Flemish University Associations). Porphyrio will leverage the new round of funding to continue enhancing its products portfolio, R&D and to drive internationalization. read more

ABLYNX ANNOUNCES WARRANT EXERCISE

18.07.2014

Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 10,000 common shares have been issued by the Company in exchange for €64,197.57 as the result of the exercise of warrants by some employees and consultants of the Company. read more

Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products

17.07.2014

BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, today announces it will lead an expert consortium which has been awarded an M-ERA.net grant totalling €576,000. The M-ERA.net EU fund supports European research collaboration programmes in materials science and engineering and health-related technology innovation. read more

Needlestick Injuries: The Avoidable Tragedy

15.07.2014

Unfortunately, needlestick injuries are still among the most common work-related ac-cidents in medical and nursing professions. Experts estimate that each employee cuts or pricks himself at least once every two years. The consequences can be devastat-ing, as in the case of Kurt Wenkenbach* (56), former manager of patient care in a nursing home. While re-capping a used insulin needle he was infected with hepatitis B and hepatitis C. The small injuries cost him his physical and mental health, and in the end his job. However, needlestick injuries and their consequences can easily be minimized by the consistent use of safety devices. read more

EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX

15.07.2014

Ablynx [Euronext Brussels: ABLX] today announced that Euronext N.V. will introduce Spotlight Options on the shares of Ablynx (option trading symbol: ABY). The options will be available as of today on the derivatives market of Euronext Brussels. read more

Internationaal competitieve Vlaamse Biobank tegen eind 2014 actief

14.07.2014

De Vlaamse biobank, met goed gekarakteriseerd menselijk lichaamsmateriaal, wordt eind december 2014 operationeel. Het doel is om hiermee translationeel biomedisch onderzoek naar innovatieve diagnostica en geneesmiddelen in de regio op een professionele manier te ondersteunen. De biobank is een initiatief van het Centrum voor Medische Innovatie vzw (CMI), opgericht als een samenwerkingsverband met alle Vlaamse universiteiten en universitaire ziekenhuizen en de industrie, met steun van de Vlaamse regering. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print